Clinical research of targeted drugs for recurrent malignant gliomas

VernacularTitle:联合靶向治疗复发恶性脑胶质瘤的研究
Author: Baoshi CHEN ¹ ; Qiang JIN ; Zhong ZHANG ; Tao JIANG
Author Information

1. 首都医科大学附属北京天坛医院神经外科
Keywords: Recurrent malignant glioma; Progressive free survival; Temozolomide; Bevacizumab
From: Chinese Journal of Neuromedicine 2015;14(7):740-742
CountryChina
Language:Chinese
Abstract: Objective To compare with the therapy effect of bevacizumab or bevacizumab combined with dose-dense temozolomide on recurrent malignant gliomas.Methods Thirty-eight patients with recurrent malignant glioma,admitted to our hospital from June 2008 to June 2012,were chosen in our study.Among them,26 patients accepted bevacizumab therapy (single drug group) and 12 accepted bevacizumab combined with dose-dense temozolomide therapy (unite drugs group).Then,the clinical data,progressive free survival (PFS) and adverse effects were retrospectively analyzed.Results Single drug group:the median PFS was 21.8 weeks,PFS-6 months was 37.8％;united drug group:the median progressive free survival was 34.7 weeks,PFS-6 months was 52.7％;significant differences were noted between the two groups (x2=8.161,P=0.023) Conclusion Bevacizumab can prolong the PFS of patients with recurrent malignant glioma;the therapy effect of bevacizumab and dose-dense temozolomide is better than single drug,which can be recommended as an effective therapy for recurrent malignant glioma.